大葉大學圖書館 |

The prostate cancer dilemma[electronic resource] :selecting patients for active surveillance, focal ablation and definitive therapy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.99463
書名/作者:	The prostate cancer dilemma : selecting patients for active surveillance, focal ablation and definitive therapy // edited by Nelson N. Stone, E. David Crawford.
其他作者:	Stone, Nelson N.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	xiv, 206 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Prostate - Cancer.
標題:	Prostate - Cancer
標題:	Prostate - Cancer
標題:	Medicine & Public Health.
標題:	Urology.
標題:	Oncology.
標題:	Pathology.
ISBN:	9783319214856
ISBN:	9783319214849
內容註:	Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.
摘要、提要註:	This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.
電子資源:	http://dx.doi.org/10.1007/978-3-319-21485-6

The prostate cancer dilemma[electronic resource] :selecting patients for active surveillance, focal ablation and definitive therapy /
The prostate cancer dilemmaselecting patients for active surveillance, focal ablation and definitive therapy /[electronic resource] :edited by Nelson N. Stone, E. David Crawford. - Cham :Springer International Publishing :2016. - xiv, 206 p. :ill., digital ;24 cm.

Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.

This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.

ISBN: 9783319214856

Standard No.: 10.1007/978-3-319-21485-6doiSubjects--Topical Terms:

340581
Prostate
--Cancer.

LC Class. No.: RC280.P7

Dewey Class. No.: 616.99463

The prostate cancer dilemma[electronic resource] :selecting patients for active surveillance, focal ablation and definitive therapy /
LDR:03313nam a2200313 a 4500 001 455162
003 DE-He213
005 20160727103415.0
006 m d
007 cr nn 008maaau
008 161227s2016 gw s 0 eng d
020 $a 9783319214856 $q (electronic bk.)
020 $a 9783319214849 $q (paper)
024 7 $a 10.1007/978-3-319-21485-6 $2 doi
035 $a 978-3-319-21485-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.P7
072 7 $a MJS $2 bicssc
072 7 $a MED088000 $2 bisacsh
082 0 4 $a 616.99463 $2 23
090 $a RC280.P7 $b P966 2016
245 0 4 $a The prostate cancer dilemma $h [electronic resource] : $b selecting patients for active surveillance, focal ablation and definitive therapy / $c edited by Nelson N. Stone, E. David Crawford.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a xiv, 206 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.
520 $a This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.
650 0 $a Prostate $x Cancer. $3 340581
650 0 $a Prostate $x Cancer $x Diagnosis. $3 464169
650 0 $a Prostate $x Cancer $x Treatment. $3 447892
650 1 4 $a Medicine & Public Health. $3 463493
650 2 4 $a Urology. $3 403368
650 2 4 $a Oncology. $3 205017
650 2 4 $a Pathology. $3 340546
700 1 $a Stone, Nelson N. $3 653276
700 1 $a Crawford, E. David. $3 653277
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-21485-6
950 $a Medicine (Springer-11650)